17,261 trials
Hypogonadism · Diabetes · Sarcopenia
Primary: Effect of Testosterone Gel vs. Anastrozole on Bone Mineral Density — 0.042; 0.008; 0.047 g/cm2
Lipoma
Primary: Change in Visible Surface Area of the Lipoma — -31.69; -47.57; -52.42; -66.60 Percent change from baseline
Pulmonary Tuberculosis
Primary: Early Bactericidal Activity (EBA) Measured as the Mean Rate of Reduction of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time…
Adenocarcinoma of the Prostate · Stage II Prostate Cancer
Primary: Comparison of Biomarkers Between Treatment Arms: Percentage Change of Tumor Cells Exhibiting Detectable Staining Within Gleason Grade 3 (GG3) Biomarker Subgroups at…
Idiopathic Pulmonary Fibrosis · Pulmonary Fibrosis
Primary: Percentage of Participants With a Treatment-Emergent Adverse Event (AE), Serious AE (SAE), Severe AE, Life-threatening AE, Death or Discontinuation Because of an AE…
Dermatitis, Atopic
Primary: Percent Change in Eczema Area Severity Index (EASI) Total Score From Baseline at Week 12 — -37.54; -38.62; -39.39 percent change
Pancreatic Acinar Cell Carcinoma · Pancreatic Ductal Adenocarcinoma · Recurrent Pancreatic Carcinoma
Primary: Overall Survival — 6.7; 3.9 months — p=0.15
Bone Pain in Stage I - III Breast Cancer
Primary: Percentage of Participants With Bone Pain (All Grades) in Cycle 1 — 46.6; 40.3; 42.5 percentage of participants
HIV Infections · Heart Disease
Primary: Bone Mineral Density (BMD) — -0.03; -0.53 percentage of change
HIV-1 Infection · HIV Infections
Primary: Safety of the DC Vaccine (as Measured by Frequency of Adverse Events) — 0; 0 participants
Traumatic Brain Injury
Primary: Safety and Tolerability of VAS203 in Patients With Moderate and Severe TBI — 8; 8; 6; 8 participants
Cancer · Carcinoma · Head and Neck Cancer
Primary: Objective Response Rate — 3.9 percentage of participants
Parkinson Disease · Accidental Falls
Primary: Change in Static Balance as Recorded Using Dynamic Posturography With the Sensory Organization Test (SOT 1-3) — -3.25; 2.05; 1.78 units on a scale — p=0.699
Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After The End of Study Therapy (SVR12) — 85.2; 75.0; 94.1; 76.9 percentage of participants
Schizophrenia
Primary: Brief Psychiatric Rating Scale (BPRS) Total Score — 44.1; 44.3 units on a scale